ANI Pharmaceuticals Inc
Research ANI Pharmaceuticals Inc (ANIP) on Bullrun: valuation model: 38.7% undervalued, market cap USD 1.74B, P/E 16.3. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerANIP
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Valuation signal38.7% undervalued
- Market capUSD 1.74B
- P/E16.3
- Financial periodQ2 2026
- RevenueUSD 266.04M
- Net incomeUSD 24.71M
- Free cash flowUSD 53.62M
- Gross margin62.4%
Valuation Snapshot
Bullrun's latest valuation model marks ANI Pharmaceuticals Inc as 38.7% undervalued; latest market cap is USD 1.74B; P/E is 16.3.
Peer valuation comparison
Latest P/E is 16.33x versus a Healthcare sector median of 24.46x (33.2% below).
Latest P/E is 16.33x versus a United States median of 24.87x (34.3% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 883.37M | USD 78.00M | USD 171.39M | 61.4% | 3.32 | USD 285.59M | USD 309.11M | USD 540.72M |
| FY2024 | USD 614.38M | -USD 19.00M | USD 47.78M | 59.3% | -1.04 | USD 144.86M | USD 318.28M | USD 403.68M |
| FY2023 | USD 486.82M | USD 19.00M | USD 110.09M | n/a | 0.85 | USD 221.12M | USD 285.67M | USD 432.75M |
| FY2022 | USD 316.39M | -USD 48.00M | -USD 40.08M | n/a | -3.05 | USD 48.23M | USD 286.52M | USD 313.69M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.74B | 16.3 | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.78B | 23.6 | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.17B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.13B | 91.9 | n/a | n/a |
| 2022 | 2022-12-30 | USD 702.17M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 775.51M | n/a | n/a | n/a |
About ANI Pharmaceuticals Inc
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products.
Related stock research
Other Healthcare stocks
Frequently asked questions
Is ANI Pharmaceuticals Inc overvalued or undervalued?
Bullrun's valuation model currently marks ANI Pharmaceuticals Inc as 38.7% undervalued.
What is ANI Pharmaceuticals Inc's market cap?
ANI Pharmaceuticals Inc's market capitalization is USD 1.74B.
What is ANI Pharmaceuticals Inc's P/E ratio?
ANI Pharmaceuticals Inc's price-to-earnings (P/E) ratio is 16.3.
What does ANI Pharmaceuticals Inc do?
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products.